Eposide 50 mg (Capsule)

Unit Price: ৳ 75.00 (5 x 6: ৳ 2,250.00)

Strip Price: ৳ 450.00

Medicine Details

Pharmacotherapeutic classification: podophyllotoxin derivatives
inhibits mitosis by blocking microtubular assembly
inhibits cell cycle progression at a premitotic phase
distribution half-life of about 1.5 hours
terminal elimination half-life ranging from 4 to 11 hours
total body clearance values range from 33 to 48 ml/min
areas under the plasma concentration vs time curves (AUC) and the maximum plasma concentration (Cmax) values increase linearly with dose
mean volumes of distribution at steady state fall in the range of 18 to 29 liters

dose ranges from 35 mg/m2/day to 50 mg/m2/day
initial dose modification based on measured creatinine clearance
subsequent Etoposide dosing should be based on patient tolerance and clinical effect

High-dose cyclosporine a resulting in concentrations above 2000 ng/ml administered with oral Eposide has led to an 80% increase in Eposide exposure
38% decrease in total body clearance of Eposide compared to Eposide alone
Periodic complete blood counts should be done during the course of Eposide treatment

Myelosuppression is dose related and dose limiting
granulocyte nadirs occurring 7 to 14 days after drug administration
platelet nadirs occurring 9 to 16 days after drug administration
Nausea and vomiting are the major gastrointestinal toxicities
Transient hypotension following rapid intravenous administration has been reported in 1% to 2% of patients
Anaphylactic-like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea, and/or hypotension have been reported

Patients must be frequently observed for myelosuppression both during and after therapy
Dose limiting bone marrow suppression is the most significant toxicity associated with Eposide therapy
The occurrence of a platelet count below 50,000/mm3 is an indication to withhold further therapy
Physicians should be aware of the possible occurrence of an anaphylactic reaction
For parenteral administration, Eposide should be given only by slow intravenous infusion
Physician must evaluate the need and usefulness of the drug against the risk of adverse reactions

Must be stored under refrigeration 2°C-8°C
stable for 24 months under refrigeration conditions
Keep all medicines out of reach of children
Protect from light
Procedure for proper handling and disposal of anticancer drugs should be considered